Register for free to listen to this article
Listen with Speechify
0:00
1:00
Akron Biotech
 
Recombinant Human Granulocyte Macrophage Colony StimulatingFactor (rHu GM-CSF) is produced in response to a number of inflammatorymediators by mesenchymal cells present in the hemopoietic environment and atperipheral sites of inflammation. GM-CSF is able to stimulate the production ofneutrophilic granulocytes, macrophages, and mixed granulocyte-macrophagecolonies from bone marrow cells and can stimulate the formation of eosinophilcolonies from fetal liver progenitor cells. GM-CSF can also stimulate somefunctional activities in mature granulocytes and macrophages. rHu GM-CSFreceptors show significant homologies with other receptors for hematopoieticgrowth factors, including IL2-beta, IL-3, IL-6, IL-7, EPO and the Prolactinreceptors. rHu GM-CSF produced in E. coli is a single, non-glycosylated,polypeptide chain that contains 127 amino acids and has a molecular mass of14.48 kDa. The product is very stable for up to three years from manufacturingdate, when stored lyophilized at -20° C.
 
 
Akron Biotech
(561) 750-6120
 www.akronbiotech.com

 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue